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Latin America, Africa, and Asia.3 If the qual›
ity of antiretroviral drugs was poor this
might lead to therapeutic or prophylactic
failure and the emergence of resistant
strains of HIV.
Establishing an effective HIV treatment
service requires high quality kits and reagents
for diagnosing and monitoring HIV/AIDS.
The sensitivity and specificity of HIV assays
decline if they are inappropriately stored or
used after their expiry date. This decline com›
promises the reliability of blood testing for
HIV before blood transfusions.4
A global strategy to tackle the HIV
epidemic must therefore incorporate regu›
lar sampling of drugs for HIV infection and
diagnostic laboratory reagents from the field
to assess drug potency and the sensitivity
and specificity of diagnostic reagents. The
addition of chemical stabilisers to drugs and
reagents may help to maintain their quality:
the least stable of the common childhood
vaccines, the oral polio vaccine, is stabilised
by the addition of pirodavir and deuterium
oxide, which allow it to resist even a 10 hour
exposure to 42oC.5
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Therapeutic consultation
centres are helpful in
developing countries
Editor—The increasing global gap between
rich and poor countries leads to inequalities
in access to drugs and to the knowledge and
skills needed for their rational use. It also
leads to qualitatively different information
needs.
Therapeutic information on the man›
agement of HIV infection and AIDS flows at
two separate levels: although some doctors
debate about the potential benefits of new
viral transmembrane protein blockers, oth›
ers are wondering how to manage a patient
with pneumocystis pneumonia because of
insufficient financial resources to purchase
co›trimoxazole. These people could benefit
from local therapeutic consultation centres,
especially in countries where the prevalence
of HIV infection and AIDS is high and
access to appropriate treatment (not only to
triple antiretroviral therapy) is unaffordable.
Therapeutic consultation centres are
one of the most relevant service activities of
clinical pharmacology,1 supplying problem
oriented information for inquiries on
individual patients or on factual
knowledge.2–5 In prevention and control
programmes for HIV infection and AIDS
such a centre specialising in managing these
conditions can give quick, expert, and locally
focused answers to common problems. For
example, it can give advice on prescription
and dose adjustments needed in special
situations such as pregnancy, paediatrics,
and anaemia; best available management for
opportunistic infections; confounding side
effects (that is, side effects not identified as
such); failure to identify drug interactions;
best alternatives when there is no drug (or
when drugs are scarce or unaffordable); and
advice when appropriate treatment proves
ineffective.
A therapeutic consultation centre could:
x Develop local guidelines
x Develop the content of and tools for
undergraduate teaching and continuous
education
x Participate in campaigns on general
health and sexual education
x Give advice to policy makers, drug regu›
latory authorities, and healthcare providers
on drug selection
x Monitor prescription and use of treat›
ment to identify inappropriate practices,
with particular emphasis on outcome
research
x Contribute to the management of inter›
national drug donations
x Design and conduct studies on specific
issues (for example, transferability of the
results of clinical trials performed in other
settings, identifying subgroups for which
evidence is lacking, cultural perceptions,
interactions with non›conventional treat›
ments, adherence).
Such a centre would need political will
and support from local authorities, training,
continuous external support, and funding. It
should include people trained in both infec›
tious diseases (particularly HIV infection
and AIDS) and clinical pharmacology, an
internet connection, and access to essential
drug information sources and medical pub›
lications. One such centre will be set up in
the Dominican Republic with the support of
the World Bank as part of the framework of
the multicountry HIV/AIDS prevention
and control programme for the Caribbean
region.
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Animal studies and HIV
research
Animal studies are inaccurate for HIV
research
Editor—As Yamey et al highlighted, HIV
will have killed 55 million people by the year
2010.1 Now, 20 years since the first
appearance of the virus, is a good time to
review the advances to date and identify
promising avenues for future research.
To estimate the amount of money spent
on research on HIV and, within that, the
amount spent on animal studies is difficult.
Assessments of the efficacy of animal studies
in HIV research are, however, easier to come
by.
Thomas Insel, former director of the
Yerkes Regional Primate Center in Georgia,
said: “[An animal model] that takes 12›14
years to develop doesn’t sound to me to be
ideal . . . I can’t tell you what it is that those
studies [with chimpanzees] have given us that
has really made a difference in the way we
approach people with this disease.”2 Animal
models of HIV have been notoriously inaccu›
rate for two reasons.
Firstly, the immune response is intensely
complicated and there are many disparities
between the human immune response and
those of other animals. Secondly, viruses are
usually species specific.
In terms of treatment, the efficacy of
zidovudine—originally an anticancer drug—
was shown in 1985 from the results of in vitro
studies rather than animal research. Similarly,
combination antiretroviral therapy was devel›
oped using in vitro methods, rational drug
design, and clinical research.
In vitro research has also enabled other
advances in understanding and potentially
treating HIV. These include elucidating the
structure of the virus (and recently the rare
b12 antibody), finding that an HIV›1 entry
inhibitor could prevent HIV from fusing
with the cell membrane,3 and discovering
that certain strains of HIV do not use the
normal 2›receptor binding process but bind
directly to T helper cells via the CD8 recep›
tor.4 Epidemiological studies determined the
routes of HIV transmission. Gene variants
that influence HIV progression were identi›
fied using longitudinal epidemiological
cohort studies, high throughput genotyping
and polymorphism discovery methods, and
computational algorithms to detect gene
associations in cohorts with the disease.5
The fact that 20 years on there is still no
cure or vaccine for HIV is surely partly
because too much money, time, and effort
have been invested in animal research which
has produced little, if nothing, in return. To
make any impact on this global pandemic
during the next 20 years, funding needs to
be concentrated on research methods that
have come up with the goods.
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